title: [Analysis of signaling pathways activated by nicotinic acetylcholine receptors in B-lymphocyte-derived cells].
abstract: The expression of nicotinic acetylcholine receptors (nAChRs) in the chicken pre-B-lymphoma DT40 cell line was investigated. DT40 cells were shown to express at least alpha7-containing nAChRs; their amount increased upon incubation with 10 microM nicotine. Addition of 10 microM choline favoured the inclusion of 3-[4.5dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide (MTT); the effect of choline was inhibited by 2.5-25 nM methyllicaconitine (MLA) or 10-100 nM alpha-cobra-toxin indicating the alpha7 nAChR role in maintaining the proliferative potential of DT40 cells. Nicotine and choline potentiated the effect of 0.5 microM ionomycin, which suppresses cell viability via Ca2+ ions influx. Contrariwise, the suppressive effect of 1 microM hydrogen peroxide, mainly affecting cell mitochondria, was weakened by choline, but was increased by 2.5 nM MLA. MEK1/2 and PKC kinases activity was necessary for maintaining the proliferative potential of DT40 cells. MLA increased the effect of the MEK1/2 kinase inhibitor (U0126), while suppressive effect of MLA itself was decreased. The presence of CaMKII kinase inhibitor (KN-62) also decreased MLA effect. MLA favoured cell survival in the presence of PKC inhibitor (chelerythrine). These data indicate that MEK1/2 and CaMKII kinases are involved in alpha7-containing nAChR signaling in DT40 cells and that PKC plays a key role in this process.
authors.forename: D M
authors.initials: DM
authors.lastname: Omel'chenko
authors.forename: O M
authors.initials: OM
authors.lastname: Kalashnyk
authors.forename: L M
authors.initials: LM
authors.lastname: Koval'
authors.forename: M V
authors.initials: MV
authors.lastname: Skok
authors.forename: S V
authors.initials: SV
authors.lastname: Komisarenko
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002645:Chickens; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007700:Kinetics; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D018722:Nicotinic Agonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: D004791:Enzyme Inhibitors; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D011493:Protein Kinase C; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D019950:Mitogen-Activated Protein Kinase 1